Montelukast Tecnigen

Montelukast, the active ingredient in Montelukast Tecnigen, is a leukotriene receptor antagonist presented as a tablet for oral use. It is indicated for maintenance therapy of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchoconstriction in adults and children. GNH USA supplies Montelukast Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control chronic airway disorders. - Asthma: reduces frequency of symptoms, nighttime awakenings and exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing, itching and rhinorrhea. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea - Dizziness - Fatigue

Serious or Rare Side Effects: - Angioedema - Stevens‑Johnson syndrome - Eosinophilic pneumonia - Hepatic injury - Anaphylaxis - Mood changes or suicidal thoughts

Before initiating therapy, consider the following safety points. - Pregnancy: Category B; use only if benefit outweighs potential risk. - Breastfeeding: Monitor infant; drug may be excreted in milk. - Hepatic impairment: Dose may require adjustment; monitor liver function. - Concomitant enzyme inducers (e.g., phenobarbital, rifampin) can lower exposure. - Not indicated for acute asthma attacks; provide rescue medication separately. - Store at ambient temperature: keep below 25°C, retain in original packaging and protect from moisture.

Montelukast may interact with several medicines; review patient medication lists.

Major Interactions (Avoid): - Phenobarbital: may markedly reduce plasma concentrations of Montelukast. - Rifampin: can lower drug exposure, diminishing therapeutic effect. - Strong CYP3A4 inducers (e.g., carbamazepine): may decrease Montelukast levels.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., fluoxetine, sertraline): potential for neuropsychiatric adverse events. - Warfarin: possible alteration of INR; monitor coagulation parameters. - Antihistamines: may add to sedation or anticholinergic load; observe patient response.